Literature DB >> 1585470

Inhibition of in vitro immunoglobulin production by rapamycin.

H Luo1, H Chen, P Daloze, J Y Chang, G St-Louis, J Wu.   

Abstract

Like FK506, rapamycin, a structural analog of FK506, is a strong immunosuppressant. The immunosuppressive effect of Rapa in in vitro IgG, IgM, and IgA production by human lymphocytes was examined in this study. To inhibit spontaneous or pokeweed mitogen-stimulated production of Ig by human peripheral blood lymphocytes, about one thousandfold lower concentrations of Rapa (IC50 = 0.3 nM-2 nM) were required than of cyclosporine (IC50 = 0.3 microM-2 microM). T cells were the direct targets of Rapa, because preincubation of T cells with Rapa abolished the T cells helper effect to T-dependent Ig production. Rapa also had direct suppressive effect on B cells, since Rapa suppressed IgG production by pure B cells stimulated with IL2 and Staphylococcus aureus Cowan I. Kinetic studies measuring IgG production and cell proliferation revealed that Rapa acted at the activation stage of T and B cells. Exogenous IL2 substantially reversed the inhibitory effect of CsA but not that of Rapa in Ig production. This study is the first report on the strong suppressive effect of Rapa on human humoral immune response with a quantitative comparison with that of CsA. The underlying mechanisms are also explored. The results indicate the potential usefulness of this drug in treatment of presensitized transplantation patients, with whom cytotoxic Ab is a major obstacle to a successful transplantation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1585470     DOI: 10.1097/00007890-199205000-00019

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  EphB6 crosslinking results in costimulation of T cells.

Authors:  Hongyu Luo; Guang Yu; Yulian Wu; Jiangping Wu
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  EphB6-null mutation results in compromised T cell function.

Authors:  Hongyu Luo; Guang Yu; Johanne Tremblay; Jiangping Wu
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 3.  Kidney transplantation in highly sensitized patients: reappraisal of etiology, evaluation, and management protocols.

Authors:  R Indudhara; R B Khauli
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 4.  New immunosuppressive drugs: mechanistic insights and potential therapeutic advances.

Authors:  A W Thomson; T E Starzl
Journal:  Immunol Rev       Date:  1993-12       Impact factor: 12.988

5.  Hepatitis E in hemodialysis and kidney transplant patients in south-east Italy.

Authors:  Gaetano Scotto; Filippo Aucella; Giuseppe Grandaliano; Domenico Martinelli; Mario Querques; Antonio Gesuete; Barbara Infante; Paolo Delli Carri; Salvatore Massa; Giovanna Salatino; Fabio Bulla; Vincenzina Fazio
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

Review 6.  Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.

Authors:  Boris Decourt; Debomoy K Lahiri; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

7.  Anti-CD28 antibody- and IL-4-induced human T cell proliferation is sensitive to rapamycin.

Authors:  H Luo; H Chen; P Daloze; G St-Louis; J Wu
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

8.  The effect of cyclosporin A, FK506, and rapamycin on the murine chronic graft-versus-host response--an in vivo model of Th2-like activity.

Authors:  R V Bundick; R I Craggs; E Holness
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

9.  Effects of cyclosporine and rapamycin on immunoglobulin production by preactivated human B cells.

Authors:  H S Kim; J Raskova; D Degiannis; K Raska
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

10.  Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France.

Authors:  Florence Legrand-Abravanel; Nassim Kamar; Karine Sandres-Saune; Sebastien Lhomme; Jean-Michel Mansuy; Fabrice Muscari; Federico Sallusto; Lionel Rostaing; Jacques Izopet
Journal:  Emerg Infect Dis       Date:  2011-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.